Strengthening the Potential of Genetic Diagnoses: A Conversation With Drs. Lucy Godley and Jorge Di Paola
Dr. Laura Michaelis interviews Drs. Lucy Godley and Jorge Di Paola about the work their expert panels are doing with ClinGen.
Does Renal Function Deteriorate in Individuals With Sickle Cell Trait and Sickle Cell Disease? Now We Know
Dr. Saah and Dr. Osunkwo study renal function in individuals with sickle cell trait and sickle cell disease.
In his final President's Column as ASH President, Dr. Ken Anderson provides a thorough overview of ASH's research agenda including topics such as precision medicine, improving the state of care for VTE, epigenetic mechanisms, and stem cell biology and regenerative medicine.
Dr. Ken Anderson discusses ASH's role in health care reform.
Dr. Anderson outlines six major ASH strategic initiatives and goals for the coming years discussed at the 2017 Executive Committee Spring Retreat in Canada.
Dr. Anderson discusses ASH's plan to participate in the "March for Science" to advocate for innovation and education through adequate research funding.
Dr. Anderson offers insight into ASH's policy statements during this politically contentious time.
In his first President's Column, Dr. Kenneth Anderson speaks about ASH's commitment to education and to spreading awareness on important treatment advances and unprecedented scientific discoveries.
Kenneth C. Anderson, MD, highlights a recent trial about adult patients with relapsed and/or refractory Multiple Myeloma.
Lenalidomide Maintenance Therapy in Multiple MyelomaDr. Anderson has served on Celgene’s advisory board. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 366 1759 1769. McCarthy PL, Owzar
Microenvironment Induced Genomic Instability in Multiple MyelomaDr. Anderson indicated no relevant conflicts of interest. Koduru S, Wong E, Strowig T, et al. Dendritic cellmediated activation induced cytidine deaminase (AID) dependent induction of genomic instability in human myeloma. Blood. 2012 119
The Added Value of 18 F FDG PET CT in Defining Prognosis and Response in MyelomaDr. Anderson indicated no relevant conflicts of interest. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18 F FDG PET CT in
January-February 2020Volume 17, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology